(Q37885396)

24 August 2017

1 reference

title

Can anti-IgE therapy prevent airway remodeling in allergic asthma? (English)

1 reference

24 August 2017

0 references

K F Rabe

1

1 reference

24 August 2017

W J Calhoun

series ordinal

2

1 reference

24 August 2017

N Smith

series ordinal

3

1 reference

24 August 2017

P Jimenez

series ordinal

4

1 reference

24 August 2017

publication date

7 June 2011

1 reference

24 August 2017

1 reference

24 August 2017

volume

66

1 reference

24 August 2017

issue

9

1 reference

24 August 2017

page(s)

1142-1151

1 reference

The anti-inflammatory effects of omalizumab confirm the central role of IgE in allergic inflammation

24 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2011.02617.X

Clinical relevance of airway remodelling in airway diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2011.02617.X

Evidence that severe asthma can be divided pathologically into two inflammatory subtypes with distinct physiologic and clinical characteristics

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2011.02617.X

Nonpharmacological and pharmacological interventions to prevent or reduce airway remodelling

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2011.02617.X

Treatment strategies for allergy and asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2011.02617.X

Allergic and nonallergic forms of atopic diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2011.02617.X

Allergy and allergic diseases. First of two parts

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2011.02617.X

Pharmacotherapy and airway remodelling in asthma?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2011.02617.X

Differences in airway remodeling between asthma and chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2011.02617.X

Cellular network in airways inflammation and remodelling.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2011.02617.X

Biopsy markers of airway inflammation and remodelling

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2011.02617.X

Inter-relationships between airway inflammation, reticular basement membrane thickening and bronchial hyper-reactivity to methacholine in asthma; a systematic bronchoalveolar lavage and airway biopsy analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2011.02617.X

Airway remodelling in asthma: current understanding and implications for future therapies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2011.02617.X

Airway inflammation, basement membrane thickening and bronchial hyperresponsiveness in asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2011.02617.X

Allergen-induced airway remodelling

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2011.02617.X

Asthmatic bronchial epithelium is more susceptible to oxidant-induced apoptosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2011.02617.X

Effect of ozone and nitrogen dioxide on the permeability of bronchial epithelial cell cultures of non-asthmatic and asthmatic subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2011.02617.X

Increased expression of p21(waf) cyclin-dependent kinase inhibitor in asthmatic bronchial epithelium

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2011.02617.X

Remodeling of the airway epithelium in asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2011.02617.X

The development of allergic inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2011.02617.X

Relationship of epidermal growth factor receptors to goblet cell production in human bronchi

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2011.02617.X

IL-13 and epidermal growth factor receptor have critical but distinct roles in epithelial cell mucin production

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2011.02617.X

Bronchoalveolar lavage fluid concentrations of transforming growth factor (TGF)-beta1, TGF-beta2, interleukin (IL)-4 and IL-13 after segmental allergen challenge and their effects on alpha-smooth muscle actin and collagen III synthesis by primary hu

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2011.02617.X

Transforming growth factor-beta regulates house dust mite-induced allergic airway inflammation but not airway remodeling.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2011.02617.X

Reduced lung function in a chronic asthma model is associated with prolonged inflammation, but independent of peribronchial fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2011.02617.X

Connective tissue growth factor expression is regulated by histamine in lung fibroblasts: potential role of histamine in airway remodeling.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2011.02617.X

Connective tissue growth factor: a role in airway remodelling in asthma?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2011.02617.X

Hyperplasia of smooth muscle in mild to moderate asthma without changes in cell size or gene expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2011.02617.X

Airway structural alterations selectively associated with severe asthma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2011.02617.X

Airway smooth muscle cell proliferation is increased in asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2011.02617.X

Expression of growth factors and remodelling of the airway wall in bronchial asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2011.02617.X

The involvement of matrix metalloproteinases in basement membrane injury in a murine model of acute allergic airway inflammation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2011.02617.X

Mast cells play a partial role in allergen-induced subepithelial fibrosis in a murine model of allergic asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2011.02617.X

Eosinophils in the pathogenesis of allergic airways disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2011.02617.X

4. IgE, mast cells, basophils, and eosinophils

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2011.02617.X

The role of eosinophils in the pathogenesis of asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2011.02617.X

Prolonged eosinophil production after allergen exposure in IFN-gammaR KO mice is IL-5 dependent

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2011.02617.X

Prostaglandin H2 induces the migration of human eosinophils through the chemoattractant receptor homologous molecule of Th2 cells, CRTH2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2011.02617.X

The effect of eosinophils on collagen gel contraction and implications for tissue remodelling

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2011.02617.X

A new paradigm of eosinophil granulocytes: neuroimmune interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2011.02617.X

Eosinophils: singularly destructive effector cells or purveyors of immunoregulation?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2011.02617.X

Role of interleukin-5 and eosinophils in allergen-induced airway remodeling in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2011.02617.X

Pulmonary fibrosis: pathogenesis, etiology and regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2011.02617.X

Dissociation of T helper type 2 cytokine-dependent airway lesions from signal transducer and activator of transcription 6 signalling in experimental chronic asthma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2011.02617.X

Regulation of procollagen I (α1) by interleukin‐4 in human bronchial fibroblasts: a possible role in airway remodelling in asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2011.02617.X

Reversibility of airway inflammation and remodelling following cessation of antigenic challenge in a model of chronic asthma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2011.02617.X

Prolonged allergen challenge in mice leads to persistent airway remodelling.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2011.02617.X

Increase in laminin expression in allergic airway remodelling and decrease by dexamethasone

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2011.02617.X

Fluticasone inhibits but does not reverse allergen-induced structural airway changes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2011.02617.X

Anti-proliferative and anti-remodelling effect of beclomethasone dipropionate, formoterol and salbutamol alone or in combination in primary human bronchial fibroblasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2011.02617.X

Budesonide/formoterol decreases expression of vascular endothelial growth factor (VEGF) and VEGF receptor 1 within airway remodelling in asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2011.02617.X

A role for cysteinyl leukotrienes in airway remodeling in a mouse asthma model

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2011.02617.X

Reversal of allergen-induced airway remodeling by CysLT1 receptor blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2011.02617.X

Allergic asthma and an anti-CD23 mAb (IDEC-152): results of a phase I, single-dose, dose-escalating clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2011.02617.X

Anti-CD23 monoclonal antibody, lumiliximab, inhibited allergen-induced responses in antigen-presenting cells and T cells from atopic subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2011.02617.X

A high-affinity monoclonal anti-IgE antibody for depletion of IgE and IgE-bearing cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2011.02617.X

Vaccines targeting IgE in the treatment of asthma and allergy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2011.02617.X

The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2011.02617.X

Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2011.02617.X

Omalizumab provides long-term control in patients with moderate-to-severe allergic asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2011.02617.X

Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with poorly controlled (moderate-to-severe) allergic asthma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2011.02617.X

Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2011.02617.X

Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2011.02617.X

IgE alone promotes human lung mast cell survival through the autocrine production of IL-6.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2011.02617.X

Effects of treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2011.02617.X

Eosinophils in bronchial mucosa of asthmatics after allergen challenge: effect of anti-IgE treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2011.02617.X

Effects of omalizumab and budesonide on markers of inflammation in human bronchial epithelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2011.02617.X

Human dendritic cell 1 and dendritic cell 2 subsets express FcepsilonRI: correlation with serum IgE and allergic asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2011.02617.X

Enhanced expression of high-affinity IgE receptor (Fc epsilon RI) alpha chain in human allergen-induced rhinitis with co-localization to mast cells, macrophages, eosinophils, and dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2011.02617.X

Safety and tolerability of omalizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2011.02617.X

Omalizumab: Practical considerations regarding the risk of anaphylaxis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2011.02617.X

Delayed onset and protracted progression of anaphylaxis after omalizumab administration in patients with asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2011.02617.X

Safety of anti-immunoglobulin E therapy with omalizumab in allergic patients at risk of geohelminth infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2011.02617.X

Baseline characteristics of patients enrolled in EXCELS: a cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2011.02617.X

A 15-Year Follow-up Study of Ventilatory Function in Adults with Asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2011.02617.X

10.1111/J.1398-9995.2011.02617.X

21 January 2018

Identifiers

DOI

1 reference

24 August 2017

1 reference